Trial Profile
A Randomized, Double-Blind, Multicenter Study Evaluating The Safety and Efficacy of BTDS in Subjects With Moderate to Severe Osteoarthritis Pain. Includes a 52-Week Extension Phase.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Sep 2012
Price :
$35
*
At a glance
- Drugs Buprenorphine (Primary)
- Indications Musculoskeletal pain
- Focus Adverse reactions; Registrational
- Sponsors Purdue Pharma
- 08 Jun 2010 New trial record.